Mettler-Toledo International (MTD) Q4 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2024 earnings summary
8 Jul, 2026Executive summary
Achieved strong Q4 2024 results with 12% sales growth in local currency and USD, and 32% increase in adjusted EPS, driven by robust demand for Laboratory products, especially in Europe, and solid execution of margin improvement initiatives.
Full-year 2024 saw 2% sales growth to $3.872B, 8% adjusted EPS growth to $41.11, and $900.6M in adjusted free cash flow, despite soft market conditions.
Continued focus on innovation, automation, and digitalization to drive future growth and market share, including launch of new platforms and digital products.
Maintained market leadership and prioritized growth in 2025 by leveraging automation, digitalization, and high-growth segments.
Financial highlights
Q4 2024 sales: $1.045B, up 12% year-over-year; Americas +7%, Europe +19%, Asia/ROW +14%.
Q4 gross margin: 61.2%, up 220 bps; adjusted operating profit: $351.9M (+25%); adjusted operating margin: 33.7% (+360 bps).
Full-year adjusted operating profit: $1.2B, up 4%; adjusted operating margin: 31.0% (+60 bps); adjusted EPS: $41.11, up 8%.
Adjusted free cash flow: $900.6M, over 100% of adjusted net income.
Outlook and guidance
2025 guidance: local currency sales growth ~3% (4.5% ex-shipping delays); adjusted EPS $42.35–$43, up 3–5% (9–10% ex-shipping delays and FX).
Q1 2025: local currency sales expected to decline 3–4% (up 2–3% ex-shipping delays); adjusted EPS $7.75–$7.95, down 11–13% (up 7–9% ex-shipping delays and FX).
Guidance includes headwinds from prior shipping delays, adverse currency impacts, and assumes current FX rates and ongoing geopolitical risks.
Latest events from Mettler-Toledo International
- Q3 2025 delivered strong sales and EPS growth, with innovation and resilience amid tariff headwinds.MTD
Q3 20259 Jul 2026 - Q2 sales fell 4% but net earnings rose 4% and full-year EPS guidance was raised.MTD
Q2 20248 Jul 2026 - 2026 guidance targets 4% revenue growth, margin expansion, and full tariff mitigation.MTD
44th Annual J.P. Morgan Healthcare Conference8 Jul 2026 - Q4 2025 delivered 8% sales and EPS growth, with a strong outlook for 2026.MTD
Q4 20258 Jul 2026 - Strong Q1 growth, tariff mitigation, and margin initiatives position the business for resilience.MTD
Bank of America 2025 Healthcare Conference8 Jul 2026 - Q1 sales fell 5% to $883.7M, but margin gains and lab growth offset tariff headwinds.MTD
Q1 20258 Jul 2026 - Adjusted EPS up 9% and sales up 7% in Q1 2026, with raised full-year EPS guidance.MTD
Q1 202614 May 2026 - Strong earnings, innovation, and China-led growth support a positive second-half outlook.MTD
Bank of America Global Healthcare Conference 202613 May 2026 - Annual meeting covers director elections, auditor ratification, and performance-based executive pay.MTD
Proxy Filing18 Mar 2026